Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319419 | 0.94 | KDM4E (0.68) | KDM4EALDH1A1KMT2APOLBACHE | |
| SCHEMBL3318235 | 0.91 | KDM4E (0.71) | KDM4EALDH1A1KMT2APOLBACHE | |
| SCHEMBL3314542 | 0.91 | KDM4E (0.71) | KDM4EALDH1A1KMT2APOLBPDE5A | |
| SCHEMBL3314425 | 0.90 | KDM4E (0.70) | KDM4EALDH1A1KMT2APOLBACHE | |
| SCHEMBL3310748 | 0.90 | KDM4E (0.70) | KDM4EALDH1A1KMT2APOLBACHE | |
| SCHEMBL3312732 | 0.88 | ACHE (0.59) | KMT2AACHE | |
| SCHEMBL3314287 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1KMT2APOLBACHE | |
| SCHEMBL3314128 | 0.85 | ACHE (0.71) | KMT2AACHEMAOBMAOA | |
| SCHEMBL22420541 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1KMT2APOLBMAOB | |
| SCHEMBL22420546 | 0.85 | MAOB (0.72) | KDM4EALDH1A1KMT2APOLBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008045663-A2 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | PDE4A, PDE4B, PDE4C | KDM4E 332/4885ALDH1A1 576/4885KMT2A 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.